MENU
FBRX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Forte Biosciences (FBRX) Earnings Date & Reports
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications... Show more
A.I. Advisor
published Earnings
FBRX is expected to report earnings to fall 20.97% to -98 cents per share on August 17
Q2'26
Est.
$-0.98
Q1'26
Missed
by $0.03
Q4'25
Missed
by $1.31
Q3'25
Missed
by $0.91
Q2'25
Missed
by $0.74
The last earnings report on May 11 showed earnings per share of -124 cents, missing the estimate of -121 cents. With 408.71K shares outstanding, the current market capitalization sits at 338.31M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information
General Information
a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer
Industry Biotechnology
Profile
Details
Industry
N/A
Address
3060 Pegasus Park Drive
Phone
+1 310 618-6994
Employees
19
Web
https://www.fortebiorx.com